GemPharmatech Advances Expansion Strategy with New Facility in San Diego
The CRO is expanding its headquarters to include a comprehensive laboratory and rodent vivarium, which enhances its preclinical research infrastructure in the U.S.
CRO that specializes in genetically engineered mouse models and preclinical services, GemPharmatech, has expanded its U.S. headquarters in San Diego, Calif., enhancing its preclinical research infrastructure. According to an April 17, 2025 press release, the expansion, which will support biomedical research and pharmaceutical development, marks a significant milestone in the company’s expansion strategy into the North American region (1).
“Our San Diego headquarters embody our vision of collaborative, innovation-driven scientific advancement,” said Dr. Xiang Gao, Founder and Chairman of GemPharmatech, in the press release (1). “With this new facility, we have expanded our global capabilities and is a sign of our continued commitment to support breakthroughs in biomedical research and therapeutic development.”
The newly built facility includes a state-of-the-art rodent vivarium and dedicated laboratory space, providing U.S.-based researchers with access to a variety of amenities, such as breeding services, vivarium rental, and preclinical in-vivo pharmacology solutions. Additionally, the new facility features modern environmental controls, which allows researchers to maintain high animal welfare standards and data quality.
“We’re thrilled to expand our capabilities in North America with this new San Diego facility,” added Dr. Brandy Wilkinson, CEO of GemPharmatech’s U.S. division, in the press release (1). “This facility gives our clients in the U.S. the technical expertise and preclinical in vivo pharmacology solutions needed to bring new therapies to market faster, along with a direct pipeline to the largest mouse model library in the world.”
On April 1, 2025, GemPharmatech announced that it had entered into the Japanese market by establishing a dedicated presence within the Shonan Health Innovation Park (Shonan iPark) (2). Through this presence, the company hopes to support Japan’s research organizations, speeding up their R&D processes.
“Japan has long been a key player in global biomedical research,” said Gao, in a press release about GemPharmatech’s expansion into Japan (2). “We are honored and excited to join the innovation-driven ecosystem of Shonan iPark and look forward to fostering closer collaborations with Japan's academic and industry leaders.”
The expansion into Shonen iPark marks a significant step in the global growth strategy and the new facility in San Diego marks a milestone in the North America expansion strategy for GemPharmatech. In both the presence at Shonen iPark and the new facility in San Diego, researchers can access GemPharmatech’s library of over 25,000 genetically engineered mouse models and a comprehensive selection of preclinical services.
References
GemPharmatech. GemPharmatech Significantly Expands U.S. Capabilities with New San Diego Biotech Hub Facility. Press Release, April 17, 2025.
GemPharmatech. GemPharmatech Joins Shonan Health Innovation Park, Expanding and Strengthening Research Support in Japan. Press Release, April 1, 2025.